|
December 2025 LANDMARK CLINICAL TRIAL FOR INNOVATIVE CONTRAST AGENT TO IMPROVE CARDIAC BUBBLE STUDIESFeaturing: Akhil Narang, MD
Northwestern Medicine has enrolled the first patient in a pivotal Phase 3 clinical trial evaluating ASI-02, a novel right-heart contrast agent. The study, known as ENHANCE, is designed to assess the safety and efficacy of ASI-02 compared to the current standard of manually agitated saline in patients undergoing saline contrast echocardiography, commonly referred to as a cardiac bubble study.
“There is a strong need for more consistent saline contrast to improve image quality and facilitate diagnoses in cardiac bubble studies,” says Akhil Narang, MD, director of the Echocardiography Laboratory at Northwestern University and principal investigator of the study. “This new contrast agent has the potential to streamline workflows, allowing for greater ease of use in the echo lab.” Cardiac bubble studies are essential for detecting right-to-left shunts, which can lead to cryptogenic stroke, particularly in patients under 60. Current methods require manual mixing of saline and air to create microbubbles, a process that is time-consuming, resource-intensive and prone to variability. ASI-02 aims to address these challenges by delivering a more reliable and efficient solution. |
Akhil Narang, MD, Director of the Echocardiography Laboratory, Associate Professor of Cardiology
Dr. Narang was principal investigator of this study. Refer a PatientNorthwestern Medicine welcomes the opportunity to collaborate with you in caring for your patients.
|
You May Also Like
|
|
|